Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets

Renovaro Inc., a clinical-stage precision medicine company, announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office for a new patent application titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions” (Application No. 18/058,752).

Health Technology Insights: Viz.ai Forms Alliance to Boost AI Cancer Diagnosis and Care

This patent strengthens Renovaro’s AI and machine learning intellectual property portfolio by protecting novel methods for integrating and harmonizing diverse biomedical data sources—such as genomics, electronic health records, imaging, and clinical trial data—into a standardized framework for predictive modeling.

“This patent is a strategic milestone for Renovaro,” said David Weinstein, CEO of Renovaro. “Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights.”

Health Technology Insights: bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

Key Drivers for Renovaro:

  • Expands Foundational IP: Builds on core patent (US 11,379,757), granted in July 2022, which protects machine learning pipeline optimization through advanced feature selection and model tuning.
  • Addresses Real-World Challenges: Tackles integration of siloed and heterogeneous data—an unmet need in pharmaceutical R&D and clinical practice.
  • Enhances Commercial Potential: Enables scalable, distributed computing for biomedical analytics across use cases in rare disease, clinical trials, and personalized medicine.
  • Supports Revenue Growth Strategy: Protects Renovaro’s differentiated technology approach, critical for commercial partnerships, licensing opportunities, and platform deployment in life sciences and healthcare.

The new patent introduces methods that operate across distributed and parallel computing environments, allowing for real-time, reproducible predictive analytics at scale. This infrastructure is vital as the biopharma industry increases reliance on AI to improve efficiency, reduce costs, and accelerate time-to-market for new therapies.

This patent allowance reinforces Renovaro’s commitment to building category-defining technology platforms that drive value for patients, partners, and shareholders alike.

Health Technology Insights: Clairity: First FDA-Approved AI for Breast Cancer Prediction

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – GlobeNewswire